ABVC BioPharma Receives $450,000 in Q3 Licensing Payments from OncoX Partnership
TL;DR
ABVC BioPharma gains a strategic edge with $450,000 in Q3 licensing payments from OncoX, securing future cash, equity, and royalties in the growing $469 billion cancer market.
ABVC receives $650,000 to date under its agreement with OncoX, which includes $2.5 million in cash, 5 million shares, and royalties based on future net sales.
ABVC's partnership with OncoX advances botanical-derived therapies for four cancer types, potentially improving global health outcomes in a rapidly expanding treatment market.
ABVC's oncology pipeline targets triple-negative breast cancer and other major indications with FDA-approved botanical drugs, leveraging a $105 million partnership value.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma, Inc. has received $450,000 in licensing payments from OncoX BioPharma during the third quarter of 2025, including $350,000 received in August. These payments represent continued progress under the companies' strategic licensing agreement that covers four major oncology indications: Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Myelodysplastic Syndromes, and Pancreatic Cancer.
The financial structure of the partnership entitles ABVC to $2,500,000 in cash payments and 5,000,000 OncoX shares, plus future royalties based on net sales. To date, ABVC has received $650,000 in cash payments, with $1,850,000 remaining receivable. When considering ABVC's subsidiary BioLite, the collective entitlement expands to $3.75 million in total cash consideration and 7.5 million OncoX shares, creating a framework with consolidated value exceeding $41 million excluding royalties.
The partnership's significance extends beyond immediate financial gains, as all four oncology indications have received FDA Investigational New Drug approvals, demonstrating ABVC's strong development position in botanical-derived oncology drug candidates. This positions both companies to capitalize on the substantial growth projected in the global cancer therapeutics market, which was valued at approximately $194.67 billion in 2024 and is projected to expand to $469.38 billion by 2034, growing at a compound annual growth rate of 9.2% according to industry research.
Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the execution strength of the collaboration, noting that the payments demonstrate both immediate liquidity and long-term equity value. The partnership reflects a strategic approach to combining innovation with collaboration to create sustainable value in the rapidly expanding oncology therapeutics market. The global cancer therapeutics market valuation and growth projections highlight the substantial commercial opportunity for both companies as they advance their botanical-derived oncology therapeutics toward global commercialization.
Curated from NewMediaWire
